Apellis Pharmaceuticals, Inc. (APLS) — Institutional Holders, Q2 2026
1 institutional investment managers reported a APLS position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $10.2K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
APLS 13F holders ranked 1–1 of 1
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | IFP Advisors#1 · 248 sh | 248 | $10.2K | — | -47.3% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.